AstraZeneca and the federal government disagree over what a federal district judge should do next in the drug company's 340B contract pharmacy lawsuit.
AstraZeneca and Feds Disagree Over Next Steps in 340B Contract Pharmacy Case
The federal government indicated in a court filing last week that it will appeal the court’s decision striking down and vacating the government’s letter telling drug company AstraZeneca its conditions on 340B pricing when covered entities use contract pharmacy were illegal and had to stop.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.